The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Fanapt growth of 26% year-over-year was primarily driven by the 2024 bipolar I disorder label expansion, which management identifies as the key volume catalyst.

The company launched Nirius via a pioneering direct-to-consumer (DTC) platform to bypass traditional pharmacy barriers and address a market of 70 million motion sickness sufferers.

Management attributes the Q1 sequential revenue decline to industry-standard insurance plan disruptions and deductible resets rather than a shift in underlying demand.

Strategic investments in the sales force, which grew to 300 representatives for Fanapt by year-end 2025 and 50 for Ponvory, contributed to the number of face-to-face calls in Q1 2026 being more than 80% higher than in Q1 2025.

The commercial strategy for Dysanti focuses on capturing new patient starts and facilitating switches from Fanapt to leverage meaningful net price favorability.

Hetlioz revenue continues to face pressure from generic competition, though management notes it remains the market share leader after three years of generic entry.

Full-year 2026 revenue guidance was raised to $240 million to $290 million to incorporate the initial commercial contribution from the Nirius launch.

Management expects 2026 cash burn to exceed 2025 levels due to outsized commercial investments and manufacturing costs for clinical and pre-commercial products.

Top-line Phase 3 results for tradipitant in GLP-1-induced nausea are expected by the end of 2026, aiming to confirm prior Phase 2 findings on vomiting reduction.

The PDUFA target action date for imsidolimab in generalized pustular psoriasis is set for 12/12/2026, with a commercial launch anticipated in 2027.

Vanda’s ongoing late-stage clinical studies are progressing, with top-line results for the Phase 3 study of Dysanti as a once-daily adjunctive treatment for major depressive disorder expected in Q1 2027.

A $10 million milestone payment was made to Eli Lilly in Q1 2026 following the U.S. approval of Nirius.

Management expressed concern regarding the slow recruitment and declining placebo relapse rates in U.S. schizophrenia studies, potentially requiring a modified development plan for the long-acting injectable iloperidone program.

Manufacturing payments of $11 million in Q1 2026 were significantly higher than recent quarters due to the timing of production for commercial and clinical supplies.

A $3 million variable consideration related to Ponvory net product sales remains subject to an ongoing dispute.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management set a cash-pay price of $85 per capsule, representing a 65% discount from the $255 WAC to ensure affordability in the consumer-driven motion sickness market.

The pricing strategy was designed to be competitive for motion sickness while maintaining flexibility for future high-volume indications like gastroparesis and GLP-1 adjunct therapy.

Nirius is differentiated by a lack of interaction in midazolam studies and the absence of warnings regarding contraceptive use found in competitors like aprepitant.

The product is being marketed in small increments (two capsules) to align with the specific needs of business and personal travelers.

Inventory sits slightly above four weeks, which is above the historical three-to-four-week range but consistent with recent quarters.

Management does not expect a destock, as current levels are viewed as appropriate for a product experiencing high double-digit prescription growth.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.